Maternal GLP-1 receptor activation inhibits fetal growth
Liping Qiao, Cindy Lu, Tianyi Zang, Brianna Dzyuba, Jianhua Shao
Abstract
Our study reveals a progressive decline in maternal blood glucagon-like peptide 1 (GLP-1) concentration. GLP-1 receptor agonist injection in late pregnancy significantly reduced fetal body weight, even after restoration of maternal blood glucose concentration. GLP-1 receptor activation significantly reduced the placental labyrinth area, expression of some nutrient transporters, and capillary development. Our study indicates that reducing maternal blood GLP-1 levels is a physiological adaptation process that benefits placental development and fetal growth.
Topics & Concepts
EndocrinologyInternal medicinePlacentaFetusBiologyReceptorInsulinAgonistGlucagon-like peptide-1PregnancyMedicineDiabetes mellitusType 2 diabetesGeneticsGestational Diabetes Research and ManagementBirth, Development, and HealthPregnancy and preeclampsia studies